Pediatrix Medical Group (NYSE:MD) Issues Earnings Results

Pediatrix Medical Group (NYSE:MD) posted its quarterly earnings data on Thursday. The company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.07, FiscalAI reports. The business had revenue of $501.37 million during the quarter, compared to the consensus estimate of $498.18 million. Pediatrix Medical Group had a return on equity of 20.12% and a net margin of 7.66%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.67 earnings per share.

Here are the key takeaways from Pediatrix Medical Group’s conference call:

• Strong Q3 performance: Adjusted EBITDA reached $85 million, ahead of expectations, while same-unit revenue grew as volume and pricing each contributed positively. Management narrowed full-year 2026 adjusted EBITDA guidance to $290 million–$300 million.
• Shareholder returns and balance sheet: Pediatrix repurchased just over 3 million shares during the quarter, bringing cumulative buybacks since August 2025 to 10 million shares at an average price of $23. Net leverage remained below one times adjusted EBITDA, with $312 million of cash.
• Revenue tailwinds are moderating: The company is beginning to lap prior benefits from unusually strong collection activity, which reduced quarterly pricing growth by slightly more than 100 basis points. Operating costs continued to rise, although clinical salary growth remained relatively contained at roughly 3%–3.5%.
• Growth opportunities remain selective: Pediatrix is expanding telehealth and evaluating potential acquisitions in women’s and children’s healthcare, while monitoring 2027 OB hospitalist coding changes. Management said the No Surprises Act IDR process is unlikely to be a headwind because less than 5% of business is out-of-network.

Pediatrix Medical Group Stock Up 2.0%

MD traded up $0.57 during trading on Friday, hitting $29.75. 1,114,251 shares of the company’s stock traded hands, compared to its average volume of 668,616. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 16.17 and a beta of 0.61. The company’s 50 day simple moving average is $26.93 and its two-hundred day simple moving average is $23.86. Pediatrix Medical Group has a 12-month low of $16.90 and a 12-month high of $30.55. The company has a current ratio of 2.00, a quick ratio of 1.32 and a debt-to-equity ratio of 0.68.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MD shares. Wall Street Zen upgraded shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 13th. Jefferies Financial Group cut Pediatrix Medical Group from a “buy” rating to a “hold” rating and lifted their price objective for the company from $27.00 to $28.00 in a research note on Wednesday, August 19th. Weiss Ratings raised Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 target price on shares of Pediatrix Medical Group in a research note on Wednesday, August 5th. Finally, UBS Group lifted their price target on Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $27.20.

More Pediatrix Medical Group News

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Pediatrix reported third-quarter adjusted earnings of $0.72 per share, exceeding consensus estimates of $0.63-$0.65 and rising from $0.67 a year earlier. Revenue reached $501.37 million, also above expectations of $498.18 million, while increasing 1.7% year over year. Pediatrix Medical Group Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Share repurchases helped drive the quarterly EPS beat, providing a favorable signal for per-share earnings and potentially supporting the stock’s valuation. Pediatrix Medical Group Q3 2026 Earnings
• Positive Sentiment: The earnings release showed a 20.05% return on equity and an 8.96% net margin, reinforcing the company’s profitability profile. Pediatrix Medical Group Reports Third-Quarter Results

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company’s clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.